SPDL1 and non-small cell lung carcinoma: In a cohort of 43 advanced NSCLC patients that were treated with nivolumab, high sPD-L1 levels at two months after treatment initiation, as well as increased sPD-L1 concentrations during treatment were associated with poor response and an absence of clinical benefit [80].